An early clinical trial has reported striking results for a new treatment for pancreatic cancer, one of the hardest cancers to treat. The findings, presented at the EORTC-NCI-AACR Symposium in Barcelona in November 2026, come from a phase 1/2 trial testing a daily oral medication called daraxonrasib alongside two standard chemotherapy drugs, gemcitabine and nab-paclitaxel. The trial included 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease. Over a median follow-up of 18 months, tumours shrank in 60.7 percent of patients, including 8.2 percent in whom tumours disappeared entirely on scans, and the combination stopped tumour growth in 90.2 percent of participants. Patients went a median of 12.8 months before their cancer worsened, almost double the time typically seen with standard chemotherapy.
What the Evidence Shows
Pancreatic cancer is particularly difficult to treat because more than half of patients are diagnosed after the disease has already spread, and most tumours carry a mutation in a gene called KRAS that drives their growth. Daraxonrasib is designed to switch off that growth signal, something scientists long thought impossible to fix with medication. The study was led by Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who said the team was seeing substantial tumour shrinkage and durable disease control, with median progression-free survival exceeding one year. Three quarters of patients, 76.6 percent, were still alive at the one-year mark. Larger trials will now test whether the benefit holds in more patients. The drug belongs to a new class of medicines that target KRAS, a protein that was considered undruggable for decades because of its smooth, featureless surface. Reporting and analysis from sources such as NASA track the same developments, and specialists following the daraxonrasib pancreatic cancer trial say the direction is now consistent across independent lines of evidence.
The Wider Context
Funding bodies are watching the daraxonrasib pancreatic cancer trial closely because the work sits at the junction of basic curiosity and practical return. Grant panels increasingly ask for a path from discovery to application, while researchers push back that the most valuable uses of fundamental science are rarely the ones written into the original proposal. The tension is productive when both sides stay honest about timescales.
What Happens Next
The long view on the daraxonrasib pancreatic cancer trial is that fields advance by accumulation rather than by single announcements. This result adds a solid, checkable piece to a structure many teams are building, and its authors have shared their data so the piece can be tested from every side. That is how the picture eventually becomes reliable enough to act on. You can follow related developments in our coverage of science.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.

